Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS
N03AF Carboxamide derivatives
N03AF03 Rufinamide
D05775 Rufinamide (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Anticonvulsants
Sodium Channel Agents
Rufinamide
D05775 Rufinamide (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
113 Antiepileptics
1139 Others
D05775 Rufinamide (JAN/USP/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03199 Antiepileptic agent
DG02034 Carboxamide antiepileptic
D05775 Rufinamide
Metabolizing enzyme substrate
DG02970 CES substrate
D05775 Rufinamide
Drug classes [BR:br08332]
Neuropsychiatric agent
DG03199 Antiepileptic agent
D05775 Rufinamide
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Sodium channels
SCN1A
D05775 Rufinamide (JAN/USP/INN) <JP/US>
SCN2A
D05775 Rufinamide (JAN/USP/INN) <JP/US>
SCN3A
D05775 Rufinamide (JAN/USP/INN) <JP/US>
SCN4A
D05775 Rufinamide (JAN/USP/INN) <JP/US>
SCN5A
D05775 Rufinamide (JAN/USP/INN) <JP/US>
SCN8A
D05775 Rufinamide (JAN/USP/INN) <JP/US>
SCN9A
D05775 Rufinamide (JAN/USP/INN) <JP/US>
SCN10A
D05775 Rufinamide (JAN/USP/INN) <JP/US>
SCN11A
D05775 Rufinamide (JAN/USP/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05775
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05775
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05775
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05775
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D05775